$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

예후가 좋지 않은 갑상선암에 대한 최신 치료 방침
Recent Improvements in the Treatment of High-Risk Thyroid Cancer 원문보기

대한 두경부 종양 학회지 = Korean journal of head & neck oncology, v.38 no.1, 2022년, pp.1 - 9  

이은경 (국립암센터 갑상선암센터 내분비내과)

Abstract ▼ AI-Helper 아이콘AI-Helper

Thyroid cancer is one of the slow-growing tumors with excellent oncological outcomes. However, a small set of patients with unexpectedly severe outcomes are usually ignored. Anaplastic thyroid cancer (ATC) remains one of the most aggressive and lethal solid tumors. Recently, dabrafenib and trametini...

주제어

#Thyroid cancer   #High risk   #Treatment   #Systemic  

참고문헌 (32)

  1. Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic"-screening and overdiagnosis. N Engl J Med. 2014;371:1765-1767. 

    상세보기

  2. Yi KH, Lee EK, Kang H-C, Koh Y, Kim SW, Kim IJ, et al. 2016 revised Korean thyroid association management guidelines for patients with thyroid nodules and thyroid cancer. IJT. 2016;9:59-126. 

  3. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA. 2021;71:7-33. 

  4. Registry KCC. Annual report of cancer statistics in Korea in 2018. Ministry of Health and Welfare; 2020. 

  5. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2021;71:209-249. 

  6. Hong S, Won Y-J, Lee JJ, Jung K-W, Kong H-J, Im J-S, et al. Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2018. Cancer Res Treat. 2021;53:301. 

    상세보기

  7. Gottlieb JA, Hill CS, Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med. 1974;290:193-197. 

    상세보기

  8. Network NCC. Thyroid Carcinoma; 2009. 

  9. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1-133. 

  10. Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa Sylvia L, et al. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690. 

    상세보기

  11. National Comprehensive Cancer Network. Thyroid Carcinoma V.1.2021; 2021. 

  12. Yoo S-K, Song YS, Park YJ, Seo J-S. Recent improvements in genomic and transcriptomic understanding of anaplastic and poorly differentiated thyroid cancers. ENM. 2020;35:44-54. 

  13. Cancer Genome Atlas Research N. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690. 

    상세보기

  14. Song YS, Park YJ. Genomic characterization of differentiated thyroid carcinoma. ENM. 2019;34:1-10. 

  15. Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. The Lancet. 2014;384:319-328. 

  16. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621-630. 

    상세보기

  17. Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, et al. The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: Establishing a standard for patient safety and monitoring. J Clin Endocrinol Metab. 2013;98:31-42. 

    상세보기

  18. Lee EK, Kim SM, Kim BH, Kim MJ, Lim DJ, Kim MH, et al. Lesion-based evaluation predicts treatment response to lenvatinib for radioactive iodine-refractory differentiated thyroid cancer: A Korean multicenter retrospective study. Thyroid. 2019;29:1811-1819. 

    상세보기

  19. Kim M, Kim TH, Shin DY, Lim DJ, Kim EY, Kim WB, et al. Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma: A Korean multicenter study. Thyroid. 2018;28:340-348. 

    상세보기

  20. Yan Z, Yang M, Lai CL. Clinical efficacy of lenvatinib for the treatment of radioiodine-refractory thyroid carcinoma: A systematic review and meta-analysis of clinical trials. Clin Endocrinol (Oxf). 2021;95:478-488. 

  21. Brose MS, Schlumbeger M, Jeffers M, Kappeler C, Meinhardt G, Pena CE. Analysis of biomarkers and association with clinical outcomes in patients with differentiated thyroid cancer: Subanalysis of the sorafenib phase 3 DECISION trial. Clin Cancer Res. 2019;25:7370-7380. 

  22. Brose MS, Frenette CT, Keefe SM, Stein SM. Management of sorafenib-related adverse events: A clinician's perspective. Semin Oncol. 2014;41 Suppl 2:S1-S16. 

  23. Drilon A. TRK inhibitors in TRK fusion-positive cancers. Annals of Oncology. 2019;30:viii23-viii30. 

    상세보기

  24. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med. 2018;378:731-739. 

    상세보기

  25. Cocco E, Scaltriti M, Drilon A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat Rev Clin Oncol. 2018;15:731-747. 

    상세보기

  26. Cocco E, Schram AM, Kulick A, Misale S, Won HH, Yaeger R, et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nature Medicine. 2019;25:1422-1427. 

  27. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020;383:825-835. 

    상세보기

  28. Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): A multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9:491-501. 

    상세보기

  29. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36:7. 

    상세보기

  30. Maniakas A, Dadu R, Busaidy NL, Wang JR, Ferrarotto R, Lu C, et al. Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000-2019. JAMA Oncology. 2020;6:1397-1404. 

    상세보기

  31. Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark Jr TJ, et al. 2021 american thyroid association guidelines for management of patients with anaplastic thyroid cancer: American thyroid association anaplastic thyroid cancer guidelines task force. Thyroid. 2021;31:337-386. 

    상세보기

  32. Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of lenvatinib and pembrolizumab is an effective treatment option for anaplastic and poorly differentiated thyroid carcinoma. Thyroid. 2021;31:1076-1085. 

    상세보기

관련 콘텐츠

오픈액세스(OA) 유형

GOLD(Hybrid)

저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로